http://www.w3.org/ns/prov#value | - days of treatmentPrior therapy with experimental anti-tumor vaccines any T cell co-stimulation or checkpoint pathways, such as anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, including Ipilimumab or other medicines specifically targeting T cell is also prohibitedSponsor:Bristol-Myers Squibb CompanyDates:02/04/2014Last Updated:Study HIC#:1311013060For more information about
|